Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 07 Jun 2016 Results from phase Ib portion of this study (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 13 Jan 2016 Planned end date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 13 Jan 2016 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2016, as reported by ClinicalTrials.gov.